MX2009006091A - Uso de agonistas de interlucina-27 para reducir aborto inmunomediado. - Google Patents

Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.

Info

Publication number
MX2009006091A
MX2009006091A MX2009006091A MX2009006091A MX2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A MX 2009006091 A MX2009006091 A MX 2009006091A
Authority
MX
Mexico
Prior art keywords
agonists
immune mediated
reduce immune
abortion
mediated abortion
Prior art date
Application number
MX2009006091A
Other languages
English (en)
Inventor
Odile Devergne
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2009006091A publication Critical patent/MX2009006091A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Se proveen citocinas y métodos para modular la tolerancia materna a un feto utilizando agonistas de IL-27; también se proporcionan métodos para modular la implantación de un embrión en un revestimiento uterino, y métodos de diagnóstico.
MX2009006091A 2006-12-07 2007-12-05 Uso de agonistas de interlucina-27 para reducir aborto inmunomediado. MX2009006091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86903506P 2006-12-07 2006-12-07
PCT/US2007/024869 WO2008070097A1 (en) 2006-12-07 2007-12-05 Use of il-27 agonists to reduce immune mediated abortion

Publications (1)

Publication Number Publication Date
MX2009006091A true MX2009006091A (es) 2009-08-18

Family

ID=39185969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009006091A MX2009006091A (es) 2006-12-07 2007-12-05 Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.

Country Status (6)

Country Link
US (1) US20100150862A1 (es)
EP (1) EP2091555A1 (es)
JP (2) JP2010511710A (es)
CA (1) CA2671697A1 (es)
MX (1) MX2009006091A (es)
WO (1) WO2008070097A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2664423A1 (en) 2006-09-22 2008-03-27 St. Jude Children's Research Hospital Modulating regulatory t cell activity via interleukin 35
US20120189578A1 (en) * 2009-08-24 2012-07-26 St. Jude Children's Research Hospital Compositions and methods for potentiating interleukin-35
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
US20130183326A9 (en) 2009-11-20 2013-07-18 St. Jude Children's Research Hospital Methods and compositions for modulating the activity of the interleukin-35 receptor complex
EP2513308B1 (en) 2009-12-17 2017-01-18 Merck Sharp & Dohme Corp. Modulation of pilr to treat immune disorders
EP2687851A1 (en) * 2012-07-20 2014-01-22 Matricelab Innove Method for increasing implantation success in assisted fertilization
CN105307725B (zh) 2013-04-11 2020-06-16 布里格姆及妇女医院股份有限公司 治疗自身免疫疾病的方法和组合物
US20230167410A1 (en) * 2019-10-15 2023-06-01 Figene, Llc Prevention of recurrent miscarriages through administration of fibroblasts and fibroblast-educated paternal cells

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830451A (en) * 1996-07-19 1998-11-03 Brigham & Women's Hospital, Inc. Haematopoietic cytokine Epstein Barr virus-induced protein
ES2405506T3 (es) * 2003-10-24 2013-05-31 Nora Therapeutics, Inc. Un método para obtener datos útiles en la identificación de un paciente con riesgo de tener dificultad de llevar a término un embarazo

Also Published As

Publication number Publication date
EP2091555A1 (en) 2009-08-26
US20100150862A1 (en) 2010-06-17
JP2013018794A (ja) 2013-01-31
WO2008070097A1 (en) 2008-06-12
JP2010511710A (ja) 2010-04-15
CA2671697A1 (en) 2008-06-12

Similar Documents

Publication Publication Date Title
MX2009006091A (es) Uso de agonistas de interlucina-27 para reducir aborto inmunomediado.
MX2009003901A (es) Metodo y aparato para obstruir lumen.
GEP20135727B (en) Progesterone for preterm birth prevention
MX357354B (es) Sistemas intrauterinos, dispositivos de insercion diu, y metodos relacionados y kits de los mismos.
MY191118A (en) Use of non-digestible saccharides for giving an infant the best start after birth
WO2013096766A3 (en) System for imaging lesions aligning tissue surfaces
CL2009001528S1 (es) Automovil de competicion formado por un cuerpo anterior trapecial alargado de perfil curvo convexo y un cuerpo posterior trapecial de vertices basales redondeados que en su cara superior presenta una cavidad, a partir de la cual la superficie se rebaja en sus laterales.
MX2009008918A (es) Activacion de celulas que presentan antigeno humano a traves de clec-6.
CL2009000769A1 (es) Uso de un probiotico para mamiferos hembras embarazadas y potenciar la inmunidad de su progenie despues del nacimiento.
NZ601645A (en) Methods for improving sperm functionality comprising a pegylated binding agent
GEP20166430B (en) Treatment of excessive menstrual bleeding associated with uterine fibroids
MX2022006547A (es) Métodos para la expansión de poblaciones de células t gamma delta con agentes multivalentes y composiciones de estas.
EP4008279A3 (en) System and method for intrauterine insemination
MX2010003938A (es) Sistema y metodo para control de embrion.
CA198299S (en) Vaginal ring for estrus synchronization in the cow
EP2471538A4 (en) USE OF LPA TO PROMOTE PREGNANCY AND FERTILITY AGENT
AU318075S (en) Cabin for working vehicles
CN203089538U (zh) 耳廓模托
IL299066A (en) Vaginal gel
UA52130U (uk) Спосіб полегшення пологів
UA33105U (ru) Способ профилактики внутриутробного инфицирования у беременных с хламидийной инфекцией
UA32373A (uk) Спосіб реабілітації жінок, які перенесли атонічні маткові кровотечі з акушерською гістеректомією
UA35176U (ru) Способ профилактики преждевременного разрыва плодных оболочек у беременных с микоуреаплазмовой инфекцией
UA66591U (ru) Способ ведения беременных с высоким риском внутриутробных инфекций
GEP20094728B (en) Use of myfepriston for anesthesia of childbirth

Legal Events

Date Code Title Description
HC Change of company name or juridical status

Owner name: NEKTAR THERAPEUTICS

FA Abandonment or withdrawal